TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
2.060
-0.040 (-1.90%)
Sep 1, 2026, 4:00 PM EDT - Market closed
TransCode Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.38 | 17.81 | 5.81 | 2.77 | 4.97 | 20.83 |
Short-Term Investments | - | - | - | - | 0.01 | 0.01 |
Cash & Short-Term Investments | 8.38 | 17.81 | 5.81 | 2.77 | 4.98 | 20.84 |
Cash Growth | 13.68% | 206.54% | 109.97% | -44.40% | -76.11% | 2406.60% |
Other Receivables | 0 | 0.95 | - | - | - | - |
Receivables | 0 | 0.95 | - | - | - | - |
Prepaid Expenses | 0.1 | 0.32 | 0.34 | 0.55 | 1.38 | 1.46 |
Other Current Assets | 2.16 | 2.9 | 0.94 | 1.14 | 1.02 | 0.44 |
Total Current Assets | 10.64 | 21.98 | 7.09 | 4.46 | 7.38 | 22.73 |
Property, Plant & Equipment | 0.32 | 0.37 | 0.09 | 0.6 | 0.21 | 0.21 |
Goodwill | 25.74 | 25.74 | - | - | - | - |
Other Intangible Assets | 114.3 | 114.3 | - | - | - | - |
Other Long-Term Assets | - | - | 0.11 | 0.11 | - | - |
Total Assets | 151.01 | 162.4 | 7.29 | 5.17 | 7.59 | 22.94 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | 4.68 | 3.49 | 2.71 | 3.05 | 4.35 | 2.5 |
Short-Term Debt | 0.65 | - | - | - | - | - |
Current Portion of Leases | - | - | 0.04 | 0.41 | - | - |
Current Unearned Revenue | 0.06 | - | 0.03 | 0.03 | - | 0.03 |
Total Current Liabilities | 5.4 | 3.49 | 2.77 | 3.49 | 4.35 | 2.53 |
Long-Term Leases | - | - | - | 0.04 | - | - |
Long-Term Deferred Tax Liabilities | 0.46 | 0.23 | - | - | - | - |
Other Long-Term Liabilities | 6.8 | 6.8 | 6.54 | - | - | - |
Total Liabilities | 12.65 | 10.52 | 9.31 | 3.53 | 4.35 | 2.53 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 94.7 | 108.2 | 61.18 | 48.06 | 31.11 | 30.71 |
Retained Earnings | -122.4 | -97.86 | -63.2 | -46.42 | -27.87 | -10.31 |
Total Common Equity | -27.7 | 10.34 | -2.02 | 1.64 | 3.24 | 20.4 |
Shareholders' Equity | 138.36 | 151.88 | -2.02 | 1.64 | 3.24 | 20.4 |
Total Liabilities & Equity | 151.01 | 162.4 | 7.29 | 5.17 | 7.59 | 22.94 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.65 | - | 0.04 | 0.45 | - | - |
Net Cash (Debt) | 7.73 | 17.81 | 5.77 | 2.32 | 4.98 | 20.84 |
Net Cash Growth | 4.83% | 208.58% | 149.15% | -53.45% | -76.11% | - |
Net Cash Per Share | 8.53 | 25.83 | 459.69 | - | - | - |
Filing Date Shares Outstanding | 16.93 | 0.92 | 0.83 | - | - | - |
Total Common Shares Outstanding | 1.01 | 0.92 | 0.04 | - | - | - |
Working Capital | 5.24 | 18.49 | 4.32 | 0.96 | 3.03 | 20.2 |
Book Value Per Share | -27.38 | 11.27 | -54.93 | - | - | - |
Tangible Book Value | -167.74 | -129.71 | -2.02 | 1.64 | 3.24 | 20.4 |
Tangible Book Value Per Share | -165.82 | -141.45 | -54.93 | - | - | - |
Machinery | 0.76 | 0.76 | 0.36 | 0.38 | 0.35 | 0.25 |